Transient phenytoin induced IgA deficiency and permanent IgE increase

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Epilepsy in children can present with complex immunological comorbidities.
• Immunoglobulin A (IgA) deficiency is a primary immunodeficiency with varied clinical manifestations.
• Antiepileptic drugs can sometimes influence immune system parameters.

Observation:

• A 9-year-old male with a 7-year history of epilepsy, commencing at 2 months of age, was studied.
• The patient exhibited absent serum and salivary IgA, alongside elevated total serum IgE, despite normal routine immunologic workups.
• Treatment with phenytoin from 2 years and 7 months of age was initiated.

Findings:

• Phenytoin withdrawal led to the normalization of IgA levels.
• Serum IgE levels progressively increased post-phenytoin withdrawal, without concurrent atopic symptoms.
• The T4 (helper)/T8 (suppressor) lymphocyte ratio showed a slight decrease, remaining within normal limits, suggesting a potential subtle T-cell imbalance.
• Phenytoin appeared to specifically modulate IgA levels, but not IgE or T-cell ratios significantly.

Implications:

• These findings suggest that the observed IgA deficiency might be secondary to an underlying primary immunoregulatory abnormality, potentially unmasked or influenced by phenytoin.
• The study highlights the importance of comprehensive immunologic monitoring in pediatric epilepsy patients undergoing long-term antiepileptic drug therapy.
• Further research is warranted to elucidate the precise mechanisms linking antiepileptic drugs, IgA deficiency, and immune dysregulation in susceptible individuals.